Your browser doesn't support javascript.
loading
Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders.
Giardina, Sarah F; Valdambrini, Elena; Singh, Pradeep K; Bacolod, Manny D; Babu-Karunakaran, Ganesh; Peel, Michael; Warren, J David; Barany, Francis.
Afiliación
  • Giardina SF; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
  • Valdambrini E; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
  • Singh PK; Department of Biochemistry, Weill Cornell Medicine, New York, New York 10065, United States.
  • Bacolod MD; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
  • Babu-Karunakaran G; Syngene International Limited, Bangalore 560 099, India.
  • Peel M; MRP Pharma LLC, Chapel Hill, North Carolina 27514, United States.
  • Warren JD; Department of Biochemistry, Weill Cornell Medicine, New York, New York 10065, United States.
  • Barany F; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
J Med Chem ; 67(7): 5473-5501, 2024 Apr 11.
Article en En | MEDLINE | ID: mdl-38554135
ABSTRACT
Proteolysis-Targeting Chimeras (PROTACs) are bifunctional molecules that bring a target protein and an E3 ubiquitin ligase into proximity to append ubiquitin, thus directing target degradation. Although numerous PROTACs have entered clinical trials, their development remains challenging, and their large size can produce poor drug-like properties. To overcome these limitations, we have modified our Coferon platform to generate Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs). CURE-PROs are small molecule degraders designed to self-assemble through reversible bio-orthogonal linkers to form covalent heterodimers. By modifying known ligands for Cereblon, MDM2, VHL, and BRD with complementary phenylboronic acid and diol/catechol linkers, we have successfully created CURE-PROs that direct degradation of BRD4 both in vitro and in vivo. The combinatorial nature of our platform significantly reduces synthesis time and effort to identify the optimal linker length and E3 ligase partner to each target and is readily amenable to screening for new targets.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Factores de Transcripción / Proteínas Nucleares Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Factores de Transcripción / Proteínas Nucleares Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos